UP!

BMRN $77.39   View long term graphs

BioMarin Pharmaceutical Inc.
Type
Public
Traded as NASDAQ: BMRN
NASDAQ-100 Component
Industry Biotechnology
Founded 1997
Founders Christopher Starr
Glen W. Denison Jr.
Headquarters San Rafael, CA, United States
Key people
Jean-Jacques Bienaime, Chief Executive Officer
Henry J. Fuchs, Chief Medical Officer
Dan Spiegelman, Chief Financial Officer
Products Kuvan, Naglazyme, Aldurazyme, Firdapse, Vimizim
Revenue Increase US$ 889 million (2015)
Operating income
Decrease US$ -171 million (2015)
Total assets Increase US$ 2.49 billion (2014)
Total equity Increase US$ 1.52 billion (2014)
Number of employees
2200 (2016)
Website www.biomarin.com
Footnotes / references

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).

BioMarin was founded in 1997 by Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and went public in 1999. Seed investors were amongst others MPM Bioventures, Grosvenor Fund and Florian Schönharting.

In 2002, BioMarin acquired Glyko Biomedical.

In 2009, BioMarin acquired Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, BioMarin was granted marketing approval by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert-Eaton myasthenic syndrome (LEMS). BioMarin launched the product under the name Firdapse.

In 2010, BioMarin acquired LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers. This acquisition was followed by the purchase of ZyStor Therapeutics, Inc. (ZyStor), a privately held biotechnology company developing ERTs for the treatment of lysosomal storage disorders and its lead product candidate, ZC-701, a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. At its R&D day in October 2010, BioMarin also announced a new program for a peptide therapeutic, vosoritide (BMN-111), for the treatment of achondroplasia.

In 2012, BioMarin acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism.

In 2014, BioMarin acquired a histone deacetylase inhibitor chemical library from Repligen for $2 million with the intention of advancing work toward therapies for Friedreich's ataxia and other neurological disorders.

In November 2014, the company agreed the acquisition of Prosensa for up to $840 million, the range of treatments for Duchenne Muscular Dystrophy however failed to attain FDA approval and in May 2016 development ceased.

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

Prosensa
(Acq 2014)

Zacharon Pharmaceuticals
(Acq 2012)

ZyStor Therapeutics, Inc.
(Acq 2010)

LEAD Therapeutics, Inc.
(Acq 2010)

Huxley Pharmaceuticals, Inc.
(Acq 2009)

Glyko Biomedical
(Acq 2002)

As of 2016, BioMarin has five products on the market, each of which is an orphan drug.

Cerliponase alfa (branded as Brineura), is an enzyme replacement treatment for Batten disease, which is a form of neuronal ceroid lipofuscinosis. It was approved in 2017.

In 2010, BioMarin became involved in controversy surrounding 3,4-diaminopyridine (3,4-DAP). BioMarin markets a phosphate salt of 3,4-DAP under the name Firdapse. In 2010, BioMarin was granted exclusive licensing rights to Firdapse for 10 years. As a result, the price of a prescribed National Health Service treatment course has increased from $1,987 for the unlicensed drug to $69,970 for Firdapse. The company states that prior to its licensing, there was no guaranteed quality control of the product and no way of formally monitoring for uncommon side effects through the regulatory process.

In 2013, BioMarin Pharmaceuticals was at the center of a high profile debate regarding expanded access of cancer patients to experimental drugs. On the advice of her doctor, Andrea Sloan, a patient with advanced ovarian cancer, requested that the company provide her with access to BMN 673, an unapproved PARP inhibitor drug candidate that had exhibited promising activity in a small Phase 1 clinical trial. The company declined, citing safety concerns. Ms. Sloan eventually received a similar drug candidate from a different company.

In 2015, there was another controversy over expanded access, concerning the supply of a drug on clinical trial to a German child who was suffering from a brain disorder but who was not part of the trial.

Use YYYY-MM-DD format for publication dates

News

BioMarin Pharmaceutical Inc. 1.06% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-02-24 Future report Set alerts
Q3 2020 2020-10-21 Future report Set alerts
Q2 2020 2020-08-04 -0.16 -0.16
Q1 2020 2020-04-29 0.44 0.44
Q4 2019 2020-02-26 0.08 0.08
Q3 2019 2019-10-23 0.30 0.30
Q2 2019 2019-08-01 -0.21 -0.21
Q1 2019 2019-04-25 -0.32 -0.32
Q4 2018 2019-02-21 -0.02 -0.03
Q3 2018 2018-10-25 -0.07 -0.07

Ratings

2016-06-22 Reiterated Rating Leerink Swann Outperform $107.00
2016-06-20 Reiterated Rating Oppenheimer Market Perform $99.00
2016-06-20 Reiterated Rating Oppenheimer Holdings Inc. Market Perform $99.00
2016-06-16 Reiterated Rating Barclays Buy
2016-06-16 Reiterated Rating Barclays PLC Buy
2016-06-13 Reiterated Rating Credit Suisse Buy $103.00 to $114.00
2016-06-13 Reiterated Rating Credit Suisse Group AG Buy $103.00 to $114.00
2016-06-10 Reiterated Rating Leerink Swann Buy
2016-06-03 Reiterated Rating Barclays Overweight $105.00
2016-06-01 Reiterated Rating Leerink Swann Buy
2016-06-01 Reiterated Rating Oppenheimer Hold $99.00
2016-06-01 Reiterated Rating Goldman Sachs Buy $126.00
2016-06-01 Reiterated Rating Goldman Sachs Group Inc. Buy $126.00
2016-05-31 Reiterated Rating RBC Capital Buy
2016-05-31 Reiterated Rating Royal Bank Of Canada Buy
2016-04-30 Reiterated Rating Cowen and Company Buy
2016-04-29 Reiterated Rating Credit Suisse Buy $114.00
2016-04-26 Reiterated Rating Oppenheimer Hold $99.00
2016-04-20 Reiterated Rating Piper Jaffray Buy
2016-04-20 Reiterated Rating Piper Jaffray Cos. Buy
2016-04-19 Reiterated Rating Wedbush Neutral $108.00
2016-04-17 Reiterated Rating Cowen and Company Buy
2016-04-08 Reiterated Rating Jefferies Group Buy $120.00 to $116.00
2016-04-07 Initiated Coverage BMO Capital Markets Outperform $99.00
2016-04-06 Reiterated Rating Oppenheimer Market Perform $99.00
2016-03-28 Reiterated Rating Piper Jaffray Overweight $107.00
2016-03-22 Reiterated Rating William Blair Buy
2016-03-22 Reiterated Rating Wedbush Neutral $108.00
2016-03-22 Lower Price Target Credit Suisse Outperform $114.00 to $109.00
2016-03-21 Reiterated Rating Piper Jaffray Overweight $107.00
2016-03-19 Reiterated Rating Leerink Swann Buy
2016-03-08 Initiated Coverage Robert W. Baird Buy
2016-03-08 Reiterated Rating JPMorgan Chase & Co. Buy
2016-03-08 Reiterated Rating Jefferies Group Buy $120.00
2016-03-07 Upgrade Goldman Sachs Buy to Conviction-Buy $129.00
2016-03-07 Upgrade Robert W. Baird Neutral to Outperform $100.00 to $110.00
2016-03-07 Reiterated Rating Cowen and Company Outperform $175.00
2016-03-05 Reiterated Rating Credit Suisse Buy
2016-03-05 Reiterated Rating Piper Jaffray Buy
2016-03-05 Reiterated Rating RBC Capital Buy
2016-03-04 Boost Price Target Wedbush Neutral $108.00
2016-03-03 Boost Price Target Credit Suisse Outperform $110.00 to $114.00
2016-03-03 Boost Price Target Stifel Nicolaus Buy $105.00 to $107.00
2016-02-29 Reiterated Rating Wedbush Neutral $117.00 to $105.00
2016-02-27 Reiterated Rating JPMorgan Chase & Co. Buy
2016-02-27 Reiterated Rating Piper Jaffray Buy
2016-02-27 Reiterated Rating RBC Capital Buy
2016-02-26 Lower Price Target JPMorgan Chase & Co. Overweight $121.00 to $117.00
2016-02-26 Lower Price Target Piper Jaffray Overweight $118.00 to $107.00
2016-02-26 Lower Price Target RBC Capital Outperform $155.00 to $125.00
2016-02-26 Lower Price Target Barclays Overweight $125.00 to $105.00
2016-02-23 Reiterated Rating Oppenheimer Market Perform $115.00 to $99.00
2016-02-23 Lower Price Target Leerink Swann Outperform $149.00 to $120.00
2016-02-22 Reiterated Rating William Blair Outperform $126.00
2016-02-19 Reiterated Rating JPMorgan Chase & Co. Overweight $141.00 to $121.00
2016-02-16 Upgrade Stifel Nicolaus Hold to Buy $105.00
2016-02-01 Reiterated Rating Wedbush Neutral $117.00
2016-01-19 Initiated Coverage Credit Suisse Outperform $110.00
2016-01-19 Lower Price Target Wedbush Neutral $125.00 to $117.00
2016-01-15 Reiterated Rating Bank of America Buy $165.00 to $135.00
2016-01-15 Reiterated Rating Leerink Swann Buy $167.00 to $149.00
2016-01-15 Lower Price Target Barclays Overweight $156.00 to $125.00
2016-01-15 Reiterated Rating Bank of America Corp. Buy $165.00 to $135.00
2016-01-14 Reiterated Rating Cowen and Company Buy
2016-01-11 Reiterated Rating JPMorgan Chase & Co. Overweight
2016-01-07 Reiterated Rating Piper Jaffray Overweight $168.00 to $118.00
2015-12-20 Reiterated Rating Piper Jaffray Buy $168.00
2015-12-18 Reiterated Rating Oppenheimer Positive $115.00
2015-12-10 Reiterated Rating Cowen and Company Buy $175.00
2015-12-08 Reiterated Rating Wedbush Neutral $125.00
2015-11-25 Reiterated Rating Bank of America Buy $165.00
2015-11-25 Reiterated Rating JPMorgan Chase & Co. Buy
2015-11-25 Lower Price Target Oppenheimer Market Perform $119.00 to $115.00
2015-11-23 Reiterated Rating Leerink Swann Buy $167.00
2015-11-23 Reiterated Rating RBC Capital Outperform $155.00
2015-11-23 Reiterated Rating Robert W. Baird Hold $147.00 to $100.00
2015-11-20 Reiterated Rating Wedbush Hold $125.00 to $137.00
2015-11-18 Initiated Coverage Goldman Sachs Buy $158.00
2015-11-17 Reiterated Rating JPMorgan Chase & Co. Buy $164.00
2015-11-17 Initiated Coverage Oppenheimer Market Perform to Market Perform $107.32 to $119.00
2015-11-13 Reiterated Rating Jefferies Group Positive to Positive $111.15 to $166.00
2015-11-02 Boost Price Target JPMorgan Chase & Co. Outperform $101.00 to $110.00
2015-10-30 Reiterated Rating Piper Jaffray Overweight $168.00
2015-10-30 Reiterated Rating JPMorgan Chase & Co. Buy
2015-10-30 Reiterated Rating Wedbush Hold $137.00
2015-10-22 Reiterated Rating Piper Jaffray Buy
2015-10-13 Reiterated Rating Raymond James Outperform $157.00
2015-10-13 Reiterated Rating Raymond James Financial Inc. Outperform $157.00
2015-10-05 Boost Price Target Wedbush Neutral $131.00 to $137.00
2015-10-02 Reiterated Rating Piper Jaffray Overweight $168.00
2015-10-02 Initiated Coverage Raymond James Outperform $148.00
2015-10-01 Reiterated Rating Cowen and Company Buy $175.00
2015-09-30 Reiterated Rating JPMorgan Chase & Co. Buy
2015-09-23 Reiterated Rating Leerink Swann Buy
2015-08-31 Initiated Coverage Raymond James Outperform $148.00
2015-08-31 Reiterated Rating Wedbush Neutral $131.00
2015-08-25 Lower Price Target Jefferies Group Buy $170.00 to $166.00
2015-08-24 Reiterated Rating Wedbush Neutral $131.00
2015-08-24 Reiterated Rating Cowen and Company Buy $175.00
2015-08-24 Reiterated Rating RBC Capital Buy $145.00
2015-08-06 Reiterated Rating Deutsche Bank Buy $160.00
2015-08-06 Reiterated Rating Deutsche Bank AG Buy $160.00
2015-08-05 Reiterated Rating William Blair Buy $160.00
2015-08-05 Reiterated Rating Wedbush Hold $130.00 to $139.00
2015-08-04 Boost Price Target Bank of America Buy $140.00 to $165.00
2015-08-04 Reiterated Rating Nomura Buy $163.00 to $173.00
2015-08-04 Reiterated Rating SunTrust Buy
2015-08-04 Boost Price Target Piper Jaffray Overweight $163.00 to $168.00
2015-08-04 Reiterated Rating Nomura Holdings Inc. Buy $163.00 to $173.00
2015-08-04 Reiterated Rating SunTrust Banks Inc. Buy
2015-07-29 Reiterated Rating Piper Jaffray Overweight $147.00 to $163.00
2015-07-27 Reiterated Rating Wedbush Neutral $130.00
2015-07-21 Reiterated Rating Leerink Swann Buy $143.00
2015-07-08 Reiterated Rating RBC Capital Outperform $145.00 to $155.00
2015-06-29 Reiterated Rating Robert W. Baird Hold $133.00
2015-06-26 Reiterated Rating Wedbush Neutral $130.00
2015-06-23 Set Price Target Nomura Buy $163.00
2015-06-19 Boost Price Target William Blair Outperform $126.00 to $140.00
2015-06-19 Reiterated Rating Wedbush Neutral $130.00
2015-06-19 Downgrade Robert W. Baird Outperform to Neutral $125.00 to $133.00
2015-06-18 Reiterated Rating Cowen and Company Outperform $150.00
2015-06-18 Boost Price Target Canaccord Genuity Buy $115.00 to $150.00
2015-06-18 Boost Price Target SunTrust Buy $151.00 to $170.00
2015-06-18 Boost Price Target Deutsche Bank Buy $140.00 to $156.00
2015-06-18 Boost Price Target Jefferies Group Buy $135.00 to $150.00
2015-06-18 Boost Price Target Barclays Overweight $150.00 to $156.00
2015-06-18 Boost Price Target JPMorgan Chase & Co. Overweight $140.00 to $151.00
2015-06-18 Boost Price Target Piper Jaffray Overweight $123.00 to $147.00
2015-06-18 Boost Price Target RBC Capital Outperform $125.00 to $145.00
2015-06-18 Boost Price Target Leerink Swann $143.00
2015-06-17 Boost Price Target Leerink Swann Outperform $136.00 to $143.00
2015-06-09 Reiterated Rating Wedbush Neutral $115.00
2015-06-05 Initiated Coverage Barclays Overweight $150.00
2015-05-28 Set Price Target Cowen and Company Buy $125.00 to $150.00
2015-05-27 Boost Price Target JPMorgan Chase & Co. Overweight $125.00 to $140.00
2015-05-23 Reiterated Rating Wedbush Neutral
2015-05-23 Reiterated Rating Jefferies Group Buy $135.00
2015-05-09 Reiterated Rating Piper Jaffray Overweight $123.00
2015-05-08 Reiterated Rating Jefferies Group Buy $135.00
2015-05-01 Reiterated Rating Piper Jaffray Overweight $123.00
2015-05-01 Reiterated Rating Wedbush Neutral $115.00
2015-05-01 Boost Price Target JPMorgan Chase & Co. Overweight $120.00 to $125.00
2015-04-23 Reiterated Rating Wedbush Neutral $104.00
2015-03-27 Boost Price Target Deutsche Bank Buy $90.00 to $140.00
2015-03-13 Boost Price Target Jefferies Group Buy $125.00 to $135.00
2015-02-26 Set Price Target Wedbush Hold $104.00
2015-02-26 Reiterated Rating Brean Capital Hold
2015-02-26 Reiterated Rating Canaccord Genuity Buy $115.00
2015-02-26 Boost Price Target JPMorgan Chase & Co. Overweight $110.00 to $120.00
2015-02-26 Reiterated Rating Citigroup Inc. Buy $94.00 to $133.00
2015-02-26 Boost Price Target Leerink Swann Outperform $107.00 to $136.00
2015-02-20 Set Price Target Wedbush Hold $102.00
2015-02-10 Boost Price Target JPMorgan Chase & Co. Overweight $101.00 to $110.00
2015-02-09 Initiated Coverage Bank of America Buy
2015-01-29 Initiated Coverage Evercore ISI Buy
2015-01-23 Boost Price Target Robert W. Baird Outperform $95.00 to $120.00
2015-01-14 Reiterated Rating Nomura Positive
2015-01-13 Set Price Target Nomura Buy $114.00 to $116.00
2015-01-12 Set Price Target RBC Capital Buy $110.00
2015-01-07 Initiated Coverage Canaccord Genuity Buy
2014-12-19 Boost Price Target RBC Capital Outperform $103.00 to $110.00
2014-12-11 Boost Price Target Nomura $114.00
2014-11-25 Boost Price Target Jefferies Group Buy $87.00 to $100.00
2014-11-25 Boost Price Target RBC Capital Outperform $87.00 to $103.00
2014-11-24 Upgrade Nomura Neutral to Buy
2014-11-10 Upgrade Goldman Sachs Neutral to Buy $78.00 to $104.00
2014-11-03 Upgrade Wells Fargo & Co. Market Perform to Outperform
2014-11-03 Upgrade Wells Fargo Market Perform to Outperform
2014-10-27 Reiterated Rating Credit Suisse Outperform $74.00 to $75.00
2014-10-27 Reiterated Rating Wedbush Neutral $76.00 to $77.00
2014-10-24 Boost Price Target RBC Capital Outperform $77.00 to $87.00
2014-10-16 Initiated Coverage SunTrust Buy $100.00
2014-09-04 Initiated Coverage Credit Suisse Outperform
2014-07-31 Boost Price Target Nomura Neutral $77.00 to $82.00
2014-06-09 Upgrade Credit Suisse Neutral to Outperform $61.74 to $73.00
2014-05-02 Lower Price Target Nomura $81.00 to $77.00
2014-04-21 Upgrade Ned Davis Research Sell to Neutral
2014-03-25 Boost Price Target Wedbush $74.00 to $76.00
2014-03-25 Downgrade Goldman Sachs Buy to Neutral $84.00
2014-03-24 Downgrade Goldman Sachs Buy to Neutral $84.00
2014-02-27 Boost Price Target Nomura $85.00 to $86.00
2014-02-27 Boost Price Target Cowen and Company $85.00 to $95.00
2014-02-19 Boost Price Target Barclays Equal Weight $73.00 to $76.00
2014-02-19 Boost Price Target Jefferies Group $83.00 to $87.00
2014-02-19 Boost Price Target Citigroup Inc. $79.00 to $90.00
2014-02-19 Boost Price Target Credit Suisse $68.00 to $73.00
2014-02-18 Boost Price Target Wedbush $72.00 to $74.00
2014-01-14 Boost Price Target Deutsche Bank Buy $75.00 to $85.00
2014-01-10 Downgrade Barclays Overweight to Equal Weight $75.00 to $73.00
2014-01-08 Initiated Coverage Nomura Neutral $75.00
2013-11-27 Reiterated Rating Piper Jaffray Overweight
2013-11-26 Initiated Coverage Piper Jaffray Overweight $87.00
2013-11-20 Reiterated Rating Barclays Buy $75.00
2013-11-20 Boost Price Target Leerink Swann Outperform $76.00 to $78.00
2013-11-19 Reiterated Rating Wells Fargo & Co. Positive
2013-11-19 Reiterated Rating Wells Fargo Positive
2013-10-25 Lower Price Target Jefferies Group Buy $86.00 to $83.00
2013-10-25 Boost Price Target Barclays Overweight $70.00 to $75.00
2013-10-25 Reiterated Rating Wedbush Hold $88.00
2013-10-22 Boost Price Target HSBC Overweight $46.00 to $50.00
2013-09-27 Reiterated Rating Wells Fargo & Co. Market Perform
2013-09-27 Reiterated Rating Wells Fargo Market Perform
2013-09-20 Boost Price Target Wedbush Neutral $63.00 to $65.00
2013-09-18 Boost Price Target William Blair $74.00 to $88.00
2013-09-18 Boost Price Target RBC Capital Outperform $66.00 to $77.00
2013-09-18 Boost Price Target Jefferies Group Buy $72.00 to $86.00
2013-09-18 Boost Price Target Goldman Sachs $76.00 to $85.00
2013-09-18 Boost Price Target Cowen and Company Outperform $79.00 to $85.00
2013-09-18 Downgrade Stifel Nicolaus Buy to Hold $70.00
2013-09-16 Reiterated Rating Bank of America Buy
2012-11-06 Downgrade Brean Capital Buy to Hold
2012-09-28 Reiterated Summer Street Research Buy $45 to $52
2012-08-27 Downgrade Deutsche Bank Buy to Hold $40 to $45
2012-03-19 Upgrade Brean Murray Hold to Buy $41
2016-06-22 Reiterated Rating Leerink Swann Outperform $107.00
2016-06-20 Reiterated Rating Oppenheimer Market Perform $99.00
2016-06-20 Reiterated Rating Oppenheimer Holdings Inc. Market Perform $99.00
2016-06-16 Reiterated Rating Barclays Buy
2016-06-16 Reiterated Rating Barclays PLC Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
BIENAIME JEAN JACQUES Chief Executive Officer 0.19%  (283979) BMRN / INCY / ITMN / PTLA / VTL /
FUCHS HENRY J EVP, Chief Medical Officer 0.11%  (156653) BMRN / GHDX / MRTX /
Davis George Eric SVP, General Counsel 0.06%  (91326) BMRN /
BAFFI ROBERT EVP, Technical Operations 0.06%  (84445) BMRN / KBIO /
SPIEGELMAN DANIEL K EVP, Chief Financial Officer 0.05%  (73587) AFFY / ANTH / BMRN / CYCC / OMER / ONTY / RLYP /
Ajer Jeffrey Robert SVP, Chief Commercial Of 0.04%  (56555) BMRN / NKTR /
HERON ELAINE J 0.03%  (38385) BMRN /
MEIER RICHARD A 0.02%  (36310) BMRN / OMI / STAA / TFX /
LAPALME PIERRE 0.02%  (30150) BMRN / INSY /
GREY MICHAEL G 0.02%  (29810) BMRN / HZNP / MRTX /
LEWIS ALAN 0.02%  (26060) ASMB / BMRN /
Mueller Brian VP, Corporate Controller 0.01%  (17559) ANTH / BMRN /
LAWLIS V BRYAN 0.01%  (13360) BMRN / GERN / KBIO /
YOUNG WILLIAM D 0.01%  (10775) BMRN / TBPH / THRX / VRTX /
BATE KENNETH 0.01%  (10775) AVEO / BMRN / CBST / EPZM / GNCA / SNTA / VNDA /
Slamon Dennis 0.01%  (9885) BMRN /

Comments